natgillin/translations-raw huggingface dataset:
Halimatoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Zdravilo Halimatoz je indicirano za zdravljenje neinfekcijskega intermediarnega, posteriornega uveitisa in panuveitisa pri odraslih bolnikih, ki se niso zadostno odzvali na zdravljenje s kortikosteroidi, pri bolnikih s potrebo po zmanjšani uporabi kortikosteroidov ali pri bolnikih, pri katerih je zdravljenje s kortikosteroidi neprimerno.
• You should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 5 months after the last Halimatoz treatment.
Nosečnost in dojenje • Premisliti morate o uporabi ustrezne kontracepcijske zaščite za preprečitev nosečnosti in z njo nadaljevati vsaj še 5 mesecev po zadnjem zdravljenju z zdravilom Halimatoz.
• Do not give Halimatoz to children with paediatric Crohn's disease below the age of 6 years.
• Zdravila Halimatoz ne smete dati otroku s Crohnovo boleznijo, če je star manj kot 6 let.
Halimatoz is intended for the treatment of the following inflammatory diseases:
Zdravilo Halimatoz je namenjeno za zdravljenje vnetnih bolezni, opisanih spodaj:
Halimatoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.
Zdravilo Halimatoz je indicirano za zdravljenje aktivnega in napredujočega psoriatičnega artritisa pri odraslih, če odziv na predhodno zdravljenje z imunomodulirajočimi antirevmatiki ni bil ustrezen.
Halimatoz works by reducing this inflammation.
Zdravilo Halimatoz deluje tako, da zmanjša tako vnetje.
Antibiotics may be continued during treatment with Halimatoz if necessary.
Med zdravljenjem z zdravilom Halimatoz lahko nadaljujete z antibiotičnim zdravljenjem, če je potrebno.
• intestinal infections (including gastroenteritis);
črevesne okužbe (vključno z virusnim gastroenteritisom),
Methotrexate should be continued during treatment with Halimatoz.
Med zdravljenjem z zdravilom Halimatoz je treba še naprej uporabljati metotreksat.
Halimatoz is injected under the skin (subcutaneous use).
Zdravilo Halimatoz se injicira pod kožo (subkutana uporaba).
Halimatoz dose for patients with polyarticular juvenile idiopathic arthritis
Odmerjanje zdravila Halimatoz pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom
• that Halimatoz treatment may increase the potential risks of o infections, including tuberculosis o cancer o nervous system problems o vaccinations
• obvestilo, da lahko zdravljenje z zdravilom Halimatoz poveča tveganje o okužb, vključno s tuberkulozo; o raka;
The Halimatoz 40 mg pre-filled syringe should not be used in children or adolescents weighing less than 40 kg with Crohn's disease, since it is not possible to administer doses less than 40 mg.
Zdravila Halimatoz 40 mg napolnjena injekcijska brizga ne smete uporabljati pri otrocih ali mladostnikih s Crohnovo boleznijo, ki tehtajo manj kot 40 kg, saj ni mogoče dati odmerka, manjšega od 40 mg.
Halimatoz dose for paediatric patients with Crohn's disease
Odmerjanje zdravila Halimatoz pri pediatričnih bolnikih s Crohnovo boleznijo
* Note: Halimatoz is currently only available as 40 mg pre-filled syringe and 40 mg pre-filled pen.
* Opomba: Zdravilo Halimatoz je trenutno na voljo samo v 40 mg napolnjeni injekcijski brizgi in 40 mg napolnjenem injekcijskem peresniku.
For patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, dyspnoea, and / or pulmonary infiltrates or other serious systemic illness with or without concomitant shock an invasive fungal infection should be suspected and administration of Halimatoz should be promptly discontinued.
Če se bolniku pojavijo znaki ali simptomi, kot so npr. zvišana telesna temperatura, splošno slabo počutje, hujšanje, znojenje, kašelj, dispneja in/ali pljučni infiltrati ali druga sistemska bolezen (s spremljajočim šokom ali brez njega), je treba posumiti na invazivno glivično okužbo.
When Halimatoz therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg for patients ≥ 30 kg may be administered one week prior to the start of maintenance therapy.
Na začetku zdravljenja z zdravilom Halimatoz se lahko pri bolnikih < 30 kg uporabi polnilni odmerek 40 mg in pri bolnikih ≥ 30 kg polnilni odmerek 80 mg en teden pred začetkom vzdrževalnegazdravljenja.
Figure A: Halimatoz pre-filled syringe with needle guard and add-on finger flange
Slika A: Napolnjena injekcijska brizga zdravila Halimatoz s ščitnikom za iglo in držalom
It is recommended that the patient should use a topical antiseptic wash on their HS lesions on a daily basis during treatment with Halimatoz.
Priporočljivo je, da med zdravljenjem z zdravilom Halimatoz bolnik vsak dan uporablja topikalno antiseptično čistilno sredstvo za čiščenje lezij HS.
If these medicines do not work well enough, you will be given Halimatoz to reduce the signs and symptoms of your disease.
Če ta zdravila ne bodo dovolj dobro delovala, boste dobili zdravilo Halimatoz za zmanjšanje znakov in simptomov vaše bolezni.
The recommended Halimatoz induction dose regimen for adult patients with moderately to severely active Crohn's disease is 80 mg at week 0 followed by 40 mg at week 2.
Priporočena shema odmerjanja zdravila Halimatoz med indukcijo je pri odraslih bolnikih z zmerno do hudo, aktivno Crohnovo boleznijo 80 mg 0. teden in nato 40 mg 2. teden.
It is recommended that paediatric patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Halimatoz therapy.
Za pediatrične bolnike je priporočljivo, da pred začetkom zdravljenja z zdravilom Halimatoz opravijo vsa cepljenja v skladu z veljavnimi smernicami za cepljenje, če je le mogoče.
Halimatoz is administered every other week via subcutaneous injection.
Zdravilo Halimatoz se odmerja vsak drugi teden v obliki subkutane injekcije.
If you have rheumatoid arthritis and you do not receive methotrexate with your Halimatoz therapy, your doctor may decide to give 40 mg adalimumab every week or 80 mg every other week.
Če imate revmatoidni artritis in če hkrati z zdravilom Halimatoz ne dobivate metotreksata, vam bo zdravnik morda predpisal 40 mg adalimumaba vsak teden ali 80 mg vsak drugi teden.
Halimatoz can slow down the damage to the cartilage and bone of the joints caused by the disease and improve physical function.
Zdravilo Halimatoz lahko upočasni napredovanje prizadetosti sklepnih hrustancev in kosti, ki jo povzroči bolezen, in izboljša telesno delovanje.
• For a more comfortable injection, take your pen out of the refrigerator 15 to 30 minutes before injecting Halimatoz to allow it to reach room temperature.
• Da bo injiciranje prijetnejše, vzemite injekcijski peresnik iz hladilnika približno od 15 do 30 minut pred injiciranjem zdravila , da se ogreje na sobno temperaturo.
Thus, it is not possible to use Halimatoz for children who require less than a full 40 mg dose.
Zato zdravila Halimatoz ni mogoče uporabljati pri otroci, ki potrebujejo manj kot polni odmerek 40 mg.
The recommended dose of Halimatoz for patients with polyarticular juvenile idiopathic arthritis from 2 years of age is based on body weight (table 1).
Priporočeni odmerek zdravila Halimatoz pri bolnikih s poliartikularnim juvenilnim idiopatskim artritisom od 2. leta starosti, temelji na telesni masi (preglednica 1).
How to use Halimatoz
Kako uporabljati zdravilo Halimatoz
If these medicines do not work well enough, patients will be given Halimatoz to treat their polyarticular juvenile idiopathic arthritis or enthesitis-related arthritis.
Če ta zdravila ne delujejo dovolj dobro, bolniki za zdravljenje poliartikularnega juvenilnega idiopatskega artritisa ali artritisa, povezanega z entezitisom, dobijo zdravilo Halimatoz.
• Do not give Halimatoz to children with paediatric plaque psoriasis or paediatric ulcerative colitis below the age of 4 years.
• Zdravila Halimatoz ne smete dati otroku z luskavico v plakih ali ulceroznim kolitisom, če je star manj kot 4 leta.
Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with Halimatoz (see section 4.4).
Oftalmologom se svetuje, da se pred začetkom zdravljenja z zdravilom Halimatoz posvetujejo z ustreznim specialistom
Halimatoz is used in adults to treat these conditions.
Zdravilo Halimatoz se uporablja za zdravljenje teh stanj pri odraslih.
Halimatoz contains sodium
Zdravilo Halimatoz vsebuje natrij
Halimatoz 40 mg solution for injection in a single-use pre-filled syringe Halimatoz is supplied in a single-use clear type I glass syringe with a rubber stopper and a stainless steel needle with an automatic needle guard with finger flange, rubber needle cap and plastic plunger, containing 0.8 ml solution.
Halimatoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi za enkratno uporabo Zdravilo Halimatoz je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo iz prozornega stekla tipa I z gumijasto zaporko in z iglo iz nerjavečega jekla z avtomatskim ščitnikom za iglo z držalom, z gumijastim pokrovčkom za iglo in s plastičnim batom, ki vsebuje 0,8 ml raztopine.
EU/1/18/1288/003 6 pre-filled syringes (3 packs of 2)
EU/1/18/1288/003 6 napolnjenih injekcijskih brizg (3 pakiranja po 2)
Children, adolescents and adults with polyarticular juvenile idiopathic arthritis Children, adolescents and adults from 2 years of age weighing 30 kg or more The recommended dose of Halimatoz is 40 mg every other week.
Otroci, mladostniki in odrasli s poliartikularnim juvenilnim idiopatskim artritisom Otroci, mladostniki in odrasli, starejši od 2 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Halimatoz je 40 mg vsak drugi teden.
The recommended dose of Halimatoz for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
Priporočeni odmerek zdravila Halimatoz pri bolnikih z ankilozirajočim spondilitisom, aksialnim spondiloartritisom brez radiografskega dokaza za AS in pri bolnikih s psoriatičnim artritisom je 40 mg adalimumaba, apliciran v enkratni subkutani injekciji vsak drugi teden.
• It is important that you tell your baby's doctors and other health care professionals about your Halimatoz use during your pregnancy before the baby receives any vaccine (for more information on vaccines see the “Warnings and precautions” section).
• Pomembno je, da obvestite zdravnika vašega dojenčka in druge zdravstvene delavce, da ste med nosečnostjo prejemali zdravilo Halimatoz, preden bo vaš dojenček prejel katerokoli cepivo.
Package leaflet: Information for the patient Halimatoz 40 mg solution for injection in pre-filled syringe adalimumab This medicine is subject to additional monitoring.
Navodilo za uporabo Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab Za to zdravilo se izvaja dodatno spremljanje varnosti.
The recommended dose of Halimatoz for adult patients with rheumatoid arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
Priporočeni odmerek zdravila Halimatoz za odrasle bolnike z revmatoidnim artritisom je 40 mg adalimumaba vsak drugi teden v enkratnem odmerku v subkutani injekciji.
The recommended dose of Halimatoz for patients with Crohn's disease from 6 to 17 years of age is based on body weight (table 4).
Priporočeni odmerek zdravila Halimatoz pri bolnikih s Crohnovo boleznijo, starih od 6 do 17 let, temelji na telesni masi (preglednica 4).
If these medicines do not work well enough, you will be given Halimatoz to treat your rheumatoid arthritis.
Če ta zdravila ne delujejo dovolj dobro, boste za zdravljenje revmatoidnega artritisa dobili zdravilo Halimatoz.
Halimatoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivnega ulceroznega kolitisa pri odraslih bolnikih, ki so se ne odzovejo zadostno na običajno zdravljenje, na primer na kortikosteroide in 6-merkaptopurin (6-MP) ali azatioprin (AZA), ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Cartons contain 1 and 2 pre-filled syringes of Halimatoz.
Škatle vsebujejo 1 in 2 napolnjena injekcijska peresnika zdravila Halimatoz.
Halimatoz is used to treat rheumatoid arthritis in adults.
Zdravilo Halimatoz se uporablja za zdravljenje revmatoidnega artritisa pri odraslih.
Halimatoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen (SensoReady) with transparent window and label.
Zdravilo Halimatoz je na voljo v injekcijski brizgi za enkratno uporabo, v injekcijskem peresniku trikotne oblike (SensoReady), s prozornim okencem in oznako.
Each syringe contains 40 mg/0.8 ml of Halimatoz.
Ena injekcijska brizga vsebuje 40 mg/0,8 ml zdravila Halimatoz.
During treatment with Halimatoz, other concomitant therapies (e.g., corticosteroids and / or immunomodulatory agents) should be optimised.
Med zdravljenjem z zdravilom Halimatoz je treba optimizirati druge sočasne terapije (npr.
Halimatoz is indicated for treatment of moderately to severely active Crohn's disease in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and / or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri odraslih bolnikih, ki se ne odzovejo na popoln in ustrezen ciklus zdravljenja s kortikosteroidom in/ali imunosupresivom, ali pa takšnega zdravljenja ne prenesejo oz. imajo zanj medicinske kontraindikacije.
Halimatoz is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age.
Zdravilo Halimatoz se uporablja za zdravljenje hidradenitis suppurativa pri odraslih in mladostnikih,
Children, adolescents and adults with enthesitis-related arthritis Children, adolescents and adults from 6 years of age weighing 30 kg or more The recommended dose of Halimatoz is 40 mg every other week.
Otroci, mladostniki in odrasli z artritisom, povezanim z entezitisom Otroci, mladostniki in odrasli, starejši od 6 let, ki tehtajo 30 kg ali več Priporočeni odmerek zdravila Halimatoz je 40 mg vsak drugi teden.
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class (SOC) and frequency in table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data).
zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do
Polyarticular juvenile idiopathic arthritis from 2 years of age
Poliartikularni juvenilni idiopatski artritis od 2. do 12. leta starosti.
Halimatoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Ankilozirajoči spondilitis (AS) Zdravilo Halimatoz je indicirano za zdravljenje hudega aktivnega ankilozirajočega spondilitisa pri odraslih, ki se na konvencionalno terapijo ne odzovejo ustrezno.
There is no relevant use of Halimatoz in children aged less than 2 years in this indication.
Uporaba zdravila Halimatoz pri otrocih, mlajših od 2 let, za to indikacijo ni primerna.
Multipack cartons contain 6 (3 packs of 2) pre-filled syringes of Halimatoz.
Škatle za večkratno pakiranje vsebujejo 6 (3 pakiranja po 2) napolnjenih injekcijskih brizg zdravila Halimatoz.
Halimatoz is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.
Uveitis pri pediatričnih bolnikih Zdravilo Halimatoz je indicirano za zdravljenje kroničnega, neinfekcijskega, anteriornega uveitisa pri bolnikih, ki so starejši od 2 let in se niso ustrezno odzvali na konvencionalno zdravljenje, ga ne prenašajo ali pri katerih konvencionalno zdravljenje ni primerno.
Halimatoz 40 mg solution for injection in pre-filled syringe Halimatoz 40 mg solution for injection in pre-filled pen
Halimatoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Halimatoz is administered by subcutaneous injection.
Zdravilo Halimatoz se uporablja kot subkutana injekcija.
If you do not respond well enough to these medicines, you will be given Halimatoz to reduce the signs and symptoms of your Crohn's disease.
Če se nanje ne boste odzvali dovolj dobro, boste za zmanjšanje znakov in simptomov Crohnove bolezni dobili zdravilo Halimatoz.
• Do not give Halimatoz to children with polyarticular juvenile idiopathic arthritis below the age of
• Zdravila Halimatoz ne smete dati otroku s poliartikularnim juvenilnim idiopatskim artritisom,
EU/1/18/1288/001 1 pre-filled syringe EU/1/18/1288/002 2 pre-filled syringes
EU/1/18/1288/001 1 napolnjena injekcijska brizga EU/1/18/1288/002 2 napolnjeni injekcijski brizgi
The recommended Halimatoz dose for patients with plaque psoriasis from 4 to 17 years of age is based on body weight (table 3).
Priporočeni odmerek zdravila Halimatoz pri bolnikih s psoriazo v plakih, starih od 4 do 17 let, temelji na telesni masi (preglednica 3).
Halimatoz dose for patients with enthesitis-related arthritis Patient weight
Odmerjanje zdravila Halimatoz pri bolnikih z artritisom, povezanim z entezitisom
Halimatoz is used to treat psoriatic arthritis in adults.
Zdravilo Halimatoz se uporablja za zdravljenje psoriatičnega artritisa pri odraslih.
Halimatoz dose for paediatric patients with plaque psoriasis Patient weight
Odmerjanje zdravila Halimatoz pri pediatričnih bolnikih s psoriazo v plakih
EU/1/18/1288/006 6 pre-filled pens (3 packs of 2)
EU/1/18/1288/006 6 napolnjenih injekcijskih peresnikov (3 pakiranja po 2)
Cartons contain 1 and 2 pre-filled pens of Halimatoz.
Škatle vsebujejo 1 in 2 napolnjeni injekcijski brizgi zdravila Halimatoz.
Thus, it is not possible to administer Halimatoz to paediatric patients that require less than a full 40 mg dose.
Zato zdravila Halimatoz ni mogoče dajati pediatričnim bolnikom, ki potrebujejo odmerek, manjši od 40 mg.
Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Halimatoz.
salicilatov, nesteroidnih protivnetnih zdravil ali analgetikov.
Halimatoz is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies.
Zdravilo Halimatoz je indicirano za zdravljenje zmerno do hudo aktivne Crohnove bolezni pri pediatričnih bolnikih (od 6. leta starosti), ki se ne odzovejo zadovoljivo na konvencionalno zdravljenje, vključno s primarno prehransko terapijo in kortikosteroidom in/ali imunomodulatorjem,
Your Halimatoz single-use pre-filled syringe with needle guard and add-on finger flange
Vaša napolnjena injekcijska brizga zdravila Halimatoz z varovalnim pokrovčkom in držalom
Halimatoz is used to treat ulcerative colitis in adults.
Zdravilo Halimatoz se uporablja za zdravljenje ulceroznega kolitisa pri odraslih.
The recommended Halimatoz dose is 80 mg at week 0 followed by 40 mg every other week starting at week 1 via subcutaneous injection.
Priporočeni odmerek zdravila Halimatoz je 80 mg v 0. tednu, ki mu sledi 40 mg vsak drugi teden z začetkom v 1. tednu, v obliki subkutane injekcije.
• skin infections (including cellulitis and shingles);
• črevesne okužbe (vključno z gastroenteritisom); • okužbe kože (vključno s celulitisom in pasovcem);
Thus, it is not possible to administer Halimatoz to patients that require less than a full 40 mg dose.
Zato zdravila Halimatoz ni mogoče dajati bolnikom, ki potrebujejo odmerek, manjši od 40 mg.
Systemic infections (including sepsis, candidiasis and influenza), intestinal infections (including gastroenteritis viral), skin and soft tissue infections (including paronychia, cellulitis, impetigo, necrotising fasciitis and herpes zoster), ear infections, oral infections (including herpes simplex, oral herpes and tooth infections), reproductive tract infections (including vulvovaginal mycotic infection), urinary tract infections (including pyelonephritis), fungal infections, joint infections
okužbe ustne votline (vključno s herpesom simpleksom, ustnim herpesom in okužbami zob), okužbe reproduktivnega trakta (vključno z vulvovaginalno mikotično okužbo), okužbe urinarnega trakta (vključno s pielonefritisom),
All patients, and in particular patients with a medical history of extensive immunosuppressant therapy or psoriasis patients with a history of PUVA treatment should be examined for the presence of nonmelanoma skin cancer prior to and during treatment with Halimatoz.
Pred zdravljenjem z zdravilom Halimatoz in med zdravljenjem z njim je treba za nemelanomskega kožnega raka pregledati vse bolnike, še zlasti pa bolnike z anamnezo intenzivne imunosupresivne terapije in bolnike s psoriazo, ki so kdaj prejemali PUVA.
Halimatoz is only available as 40 mg pre-filled syringe and 40 mg pre-filled pen.
Zdravilo Halimatoz je na voljo samo v 40 mg napolnjeni injekcijski brizgi in 40 mg napolnjenem injekcijskem peresniku.
How to store Halimatoz
Shranjevanje zdravila Halimatoz
EU/1/18/1288/004 1 pre-filled pen EU/1/18/1288/005 2 pre-filled pens
EU/1/18/1288/004 1 napolnjen injekcijski peresnik EU/1/18/1288/005 2 napolnjena injekcijska peresnika
• Halimatoz pre-filled syringe/s (see Figure A).
• napolnjen(a) injekcijski(a) peresnik(a) (glejte sliko A).
In adolescent patients with inadequate response to Halimatoz 40 mg every other week, an increase in dosage to 40 mg every week or 80 mg every other week may be considered.
Pri mladostnikih z nezadostnim odzivom na zdravilo Halimatoz 40 mg vsak drugi teden je možno razmisliti o povečanju odmerka na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz is used to treat moderate to severe plaque psoriasis in adults.
Zdravilo Halimatoz se uporablja za zdravljenje zmerne do hude luskavice (psoriaze) v plakih pri odraslih.
Talk to your doctor or pharmacist before using Halimatoz.
Pred začetkom uporabe zdravila Halimatoz se posvetujte z zdravnikom ali farmacevtom.
Be sure that you read, understand, and follow these Instructions for use before injecting Halimatoz.
Preden injicirate zdravilo Halimatoz, morate ta navodila za uporabo prebrati, razumeti in jih upoštevati.
RA study I evaluated 271 patients with moderately to severely active rheumatoid arthritis who were ≥ 18 years old, had failed therapy with at least one disease-modifying, anti-rheumatic drug and had insufficient efficacy with methotrexate at doses of 12.5 to 25 mg (10 mg if methotrexate-intolerant) every week and whose methotrexate dose remained constant at 10 to 25 mg every week.
V študiji revmatoidnega artritisa I je bilo ocenjeno 271 bolnikov z zmerno do hudo aktivnim revmatoidnim artritisom, starih ≥ 18 let, pri katerih zdravljenje z vsaj enim imunomodulirajočim antirevmatičnim zdravilom ni bilo uspešno, pri katerih metotreksat v odmerkih od 12,5 do 25 mg
Beyond 16 weeks, patients with inadequate response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg every week or 80 mg every other week.
Od 16. tedna dalje lahko bolnikom z nezadostnim odzivom na zdravilo Halimatoz 40 mg vsak drugi teden koristi povečanje odmerka na 40 mg vsak teden ali na 80 mg vsak drugi teden.